Aclarion Inc(ACON) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -7.6 | Insider Own | 29.12% | Shs Outstand | 2.5M | Perf Week | -4.06% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | 35.44% | Insider Trans | 8.81% | Shs Float | 2.0M | Perf Month | -13.65% |
| Enterprise Value | -0.01B | PEG | - | EPS next Q | -1.15 | Inst Own | 4% | Short Float | 2.4% | Perf Quarter | -15.92% |
| Income | -0.01B | P/S | 80.83 | EPS this Y | 65.27% | Inst Trans | 0.4% | Short Ratio | 0.94 | Perf Half Y | -30.06% |
| Sales | 0.00B | P/B | 0.33 | EPS next 5Y | 50.26% | ROA | -56.09% | Short Interest | 0.05M | Perf YTD | -51.2% |
| Book/sh | 6.91 | P/C | 0.4 | EPS past 3/5Y | 95.75% 83.48% | ROE | -58.97% | 52W High | -81.34% ($12.03) | Perf Year | -73.89% |
| Cash/sh | 5.66 | P/FCF | - | Sales past 3/5Y | 7.8% 9.25% | ROIC | -54.09% | 52W Low | 15.13% ($1.95) | Perf 3Y | -100% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 99.74% | Gross Margin | -267.68% | Volatility(W/M) | 3.82% 5.84% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | -123.05 | Sales Y/Y TTM | 33.07% | Oper. Margin | -11592.14% | ATR (14) | 0.15 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 16.2 | EPS Q/Q | 59.4% | Profit Margin | -10978.48% | RSI (14) | 40.71 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 16.2 | Sales Q/Q | 30.48% | SMA20 | -9.3% ($2.47) | Beta | 1.21 | Target Price | $7.75 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/08/28 | SMA50 | -8.94% ($2.46) | Rel Volume | 0.52 | Prev Close | $2.34 |
| Employees | 11 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -6.67% -16% | SMA200 | -27.09% ($3.07) | Avg Volume(3M) | 0.05M | Price | $2.24 |
| IPO | 2022/4/22 | Option/Short | No/Yes | Trades | 117 | Volume | 26,982 | Change | -4.06% |
A small-cap Nasdaq-listed healthcare technology company developing an AI-powered diagnostic SaaS that non-invasively identifies which disc in chronic lower back pain patients is the actual source of pain. Its flagship product is the Nociscan platform, which applies proprietary biomarkers and AI algorithms to magnetic resonance spectroscopy (MRS) data obtained from existing MRI equipment. The company is currently running a large-scale clinical trial (CLARITY).
Over the past 1 year, on the lower side
81% below its 1-year high.
Traded less than usual. That is 52% of its average volume.
ACON has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +65.3% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $8,083. Peers typically go for $85.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 3 years ago, your return today would be -100.0%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 4.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #38 of 42 in the industry
Based on market cap of $6M.
FAQ
What kind of company is ACON?
ACON belongs to the Healthcare sector and operates in the Health Information Services industry.
What is the market cap of ACON?
The market cap of ACON is approximately $6M, ranking 5,595 within its sector.
What is the 52-week high and low for ACON?
ACON has recorded a 52-week high of $12.03 and a low of $1.95.
